Results 91 to 100 of about 12,534 (220)

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

ChemBioChem, Volume 27, Issue 1, January 2026.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh, Rupesh R. Kurhade, Abrar A. M. Siddiqui, Shaikh Shahbaz A. Majeed, Thomas J. Webster, Mohammad Intakhab Alam, Abdul Wasy Zia, Md. Faiyazuddin   +7 more
wiley   +1 more source

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium

Pharmaceutics, 2019
Melanoma is a cancer with increasing incidence and there is a need for alternatives to immunotherapy within effective approaches to treatment of metastatic melanoma.
Kevin J. H. Allen, Rubin Jiao, Mackenzie E. Malo, Connor Frank, Darrell R. Fisher, David Rickles, Ekaterina Dadachova   +6 more
doaj   +1 more source

Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics [PDF]

, 2018
Purpose: It is generally assumed that the biodistribution and pharmacokinetics of radiolabelled antibodies remain similar between dosimetric and therapeutic injections in radioimmunotherapy.
Antonescu, Cristian, Bischof Delaloye, Angelika, Buchegger, Franz, Grannavel, Carine, Ketterer, Nicolas, Kosinski, Marek, Kovacsovics, Tibor, Monnin, Pascal, Schaffland, Andreas, Verdun, Francis   +9 more
core  

Targeted therapy in nuclear medicine—current status and future prospects [PDF]

, 2017
In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged. New developments and insights in radioiodine treatment of thyroid cancer, treatment of lymphoma and solid tumors with radiolabeled monoclonal ...
Bodei, L., Brans, B., Giammarile, F., Luster, M., Maecke, H. R., Oyen, W. J. G., Tennvall, J.   +6 more
core  

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate [PDF]

, 2009
Adequate dosimetry is mandatory for effective and safe peptide receptor radionuclide therapy (PRRT). Besides the kidneys, the bone marrow is a potentially dose-limiting organ.
Flavio Forrer, Eric P. Krenning, Peter P. Kooij, Bert F. Bernard, Mark Konijnenberg, Willem H. Bakker, Jaap J. M. Teunissen, Marion de Jong, Kirsten van Lom, Wouter W. de Herder, Dik J. Kwekkeboom   +10 more
core   +1 more source

Adaptive immunity in cancer immunology and therapeutics. [PDF]

, 2014
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core   +2 more sources

Radioimmunotherapy for Colorectal Cancer [PDF]

Clinical Cancer Research, 2005
Monoclonal antibodies, selected for their ability to recognize and bind tumor-specific antigens, are a promising vehicle for systemic antitumor therapy. Radioimmunotherapy utilizes radioisotopes conjugated to monoclonal antibodies to deliver tumoricidal radiation doses.
openaire   +2 more sources

Early Diagnosis of Alzheimer's Disease by NIRF Spectroscopy\ud and Nuclear Medicine\ud [PDF]

, 2011
Novel approaches to Early Diagnosis of Alzheimer's Disease by NIRF Spectroscopy and Nuclear Medicine are presented and related cognitive, as well as molecular and cellular, models are critically evaluated ...
Baianu, Prof.Dr. I.C.
core  

Combination of 131I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma

Biotechnology & Biotechnological Equipment, 2018
The present study aimed to investigate the therapeutic efficacy of combined radioimmunoconjugate 131I endoglin (ENG) and 5-fluorouracil (5-FU) in mouse model with hepatocellular carcinoma (HCC).
Chongling Duan, Yanxiang Li, Weifei Yang, Chao Zhang   +3 more
doaj   +1 more source

Radioimmunotherapy: a brief overview

Biomedical Imaging and Intervention Journal, 2006
With the advent of biotechnological advances and knowledge of molecular and cellular biology, radioimmunotherapy (RIT) has become a highly promising oncologic therapeutic modality with established clinically efficacy, particularly in non-Hodgkin's lymphomas.
openaire   +2 more sources